Abstract
THE hepatitis B virus (HBV) transactivator protein HBx is enigmatic in that it stimulates a striking variety of promoters which do not share a common cis-regulatory element1–5. As it does not bind to DNA6,7, it has been speculated that HBx acts indirectly through cellular pathways4,6–8. Under certain conditions HBx can have an oncogenic potential, which may be relevant for HBV-associated liver carcinogenesis9–11, but until now the mechanism for transactivation and cell transformation by HBx was unclear. We report here that HBx uses a complex signal transduction pathway for transactivation. An increase in the endogenous protein kinase C (PKC) activator sn-l,2-diacylglycerol and the subsequent activation of PKC give rise to activation of the transcription factor AP-1 (Jun–Fos). As a result, HBx transactivates through binding sites for AP-1 and other PKC-dependent transcription factors (AP-2, NF-κB), thereby explaining the as-yet incomprehensible variety of HBx-inducible genes. As the PKC signal cascade also mediates cell transformation by tumour-promoting agents, the mechanism presented here might account for the oncogenic potential of HBx.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zahm, P., Hofschneider, P. H. & Koshy, R. Oncogene 3, 169–177 (1988).
Twu, J. & Schloemer, R. H. J. Virol. 61, 3448–3453 (1987).
Spandau, D. F. & Lee, C. J. Virol. 62, 427–434 (1988).
Seto, E., Mitchell, P. J. & Yen, T. B. Nature 344, 72–74 (1990).
Rossner, M. T. J. med. Virol. 36, 101–117 (1992).
Faktor, O. & Shaul, Y. Oncogene 5, 867–872 (1990).
Siddiqui, A., Jameel, S. & Mapoles, J. Proc. natn. Acad. Scl. U.S.A. 84, 2513–2517 (1987).
Wu, J. Y., Zhuo, Z.-Y., Judd, A., Cartwright, C. A. & Robinson, W. S. Cell 63, 687–695 (1990).
Höhne, M. et al. EMBO J. 9, 1137–1145 (1990).
Kim, C.-M., Koike, K., Saito, I., Miyamura, T. & Jay, G. Nature 351, 317–320 (1991).
Seifer, M., Höhne, M., Schaefer, S. & Gerlich, W. H. J. Hepatology 13, S61–S65 (1991).
Angel, P. & Karin, M. Biochim. biophys. Acta 1072, 129–157 (1991).
Müller, U., Roberts, M. P., Engel, D. A., Doerfler, W. & Shenk, T. Genes Dev. 3, 1991–2002 (1989).
Nishizuka, Y. Nature 334, 661–665 (1988).
Büscher, M., Rahmsdorf, H. J., Litfin, M., Karin, M. & Herrlich, P. Oncogene 3, 301–311 (1988).
Lucito, R. & Schneider, R. J. J. Virol. 66, 983–991 (1992).
Exton, J. H. J. biol. Chem. 265, 1–4 (1990).
Lacal, J. C., Joscat, J. & Aaronson, S. A. Nature 220, 269–272 (1987).
Song, J., Pfeffer, L. M. & Foster, D. A. Molec. cell. Biol. 11, 4903–4908 (1991).
Wasylyk, C., Imler, J. L., Perez-Mutul, J. & Wasylyk, B. Cell 48, 525–534 (1987).
Maguire, H. F., Hoeffler, J. P. & Siddiqui, A. Science 252, 842–844 (1991).
Blum, H. E. et al. J. Virol. 66, 1223–1227 (1992).
Yaginuma, K., Shirakata, Y., Kobayashi, M. & Koike, K. Proc. natn. Acad. Sci. U.S.A. 84, 2678–2682 (1987).
Housey, G. M. et al. Cell 52, 343–354 (1988).
Baniahmad, A., Steiner, C., Köhne, A. C. & Renkawitz, R. Cell 61, 505–514 (1990).
Wollersheim, M. & Hofschneider, P. H. in Viral Hepatitis and Liver Disease (ed. Zuckermann, A. J.) 334–340 (Liss, New York, 1988).
Graham, F. L. & van der Eb, A. J. Virology 52, 456–467 (1973).
De Wet, J. R., Wood, K. V., DeLuca, M., Helinski, D. R. & Subramani, S. Molec. cell. Biol. 7, 725–737 (1987).
Gorman, C. M., Moffat, L. F. & Howard, B. H. Molec. cell. biol. 2, 1044–1051 (1982).
Angel, P. Hattori, K., Smeal, T. & Karin, M. Cell 55, 875–885 (1988).
Dignam, J. P., LeBovitz, R. M. & Roeder, R. G. Nucleic Acids Res. 11, 1475–1489 (1983).
Hidaka, H., Inagaki, M., Kawamoto, S. & Sasaki, Y. Biochemistry 23, 5036–5041 (1984).
Loomis, C. R. & Bell, R. M. J. biol. Chem. 263, 1682–1692 (1988).
Hannun, Y. A., Loomis, C. R., Merrill, A. H. & Bell., R. M. J. biol. Chem. 261, 12604–12609 (1986).
Toullec, D. et al. J. biol. Chem. 266, 15771–15781 (1991).
Tamaoki, T. et al. Biochem. biophys. Res. Commun. 135, 397–402 (1986).
Asano, T. & Hidaka, H. J. Pharmak. exp. Ther. 231, 141–145 (1984).
Konig, H. et al. EMBO J. 8, 2559–2566 (1989).
Fabbro, D., Jungmann, R. A. & Eppenberger, U. Arch. Biochem. Biophys. 239, 102–111 (1985).
Van Veldhoven, P. P. & Mannaerts, G. P. Analyt. Biochem. 161, 45–48 (1987).
Preiss, J. et al. J. biol. Chem. 261, 8597–8600 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kekulé, A., Lauer, U., Weiss, L. et al. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 361, 742–745 (1993). https://doi.org/10.1038/361742a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/361742a0
This article is cited by
-
Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis
Oncogene (2019)
-
Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover
Oncogene (2017)
-
The Chinese medicine Sini-San inhibits HBx-induced migration and invasiveness of human hepatocellular carcinoma cells
BMC Complementary and Alternative Medicine (2015)
-
Hepatitis B virus regulation of Raf1 promoter activity through activation of transcription factor AP-2α
Archives of Virology (2013)
-
Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer
Oncogene (2012)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.